Risk of male breast cancer after Hodgkin lymphoma

Simone de Vries, Inge Krul, Michael Schaapveld, Cecile M P Janus, Saskia E Rademakers, Judith M Roesink, Marten R Nijziel, Yavuz M Bilgin, Berthe M P Aleman, Flora E van Leeuwen

Research output: Contribution to journalArticleAcademicpeer-review


Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age ≤51 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10 000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10 000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.

Original languageEnglish
Pages (from-to)806-811
Number of pages6
Issue number9
Early online date30 Jun 2023
Publication statusPublished - 31 Aug 2023


Dive into the research topics of 'Risk of male breast cancer after Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this